Anthony C Keech

Summary

Affiliation: University of Sydney
Country: Australia

Publications

  1. ncbi request reprint Interpreting the results of a clinical trial
    Anthony C Keech
    NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW
    Med J Aust 186:318-9. 2007
  2. ncbi request reprint Balancing the outcomes: reporting adverse events
    Anthony C Keech
    NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia
    Med J Aust 181:215-8. 2004
  3. ncbi request reprint Urinary albumin levels in the normal range determine arterial wall thickness in adults with Type 2 diabetes: a FIELD substudy
    A C Keech
    NHMRC Clinical Trials Centre, University of Sydney, Sydney NSW 2006, Australia
    Diabet Med 22:1558-65. 2005
  4. ncbi request reprint Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial
    A C Keech
    NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia
    Lancet 370:1687-97. 2007
  5. doi request reprint Cost-effectiveness considerations of cardiovascular therapeutics
    Anthony Keech
    NHMRC Clinical Trials Centre and Department of Cardiology, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia
    Heart Lung Circ 18:118-22. 2009
  6. doi request reprint Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    Andrew Tonkin
    Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic, Australia
    Am Heart J 163:508-14. 2012
  7. pmc Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial
    Russell Scott
    Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand
    Cardiovasc Diabetol 10:102. 2011
  8. pmc Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
    Kushwin Rajamani
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
    Lancet 373:1780-8. 2009
  9. ncbi request reprint Putting results of a clinical trial into perspective
    Nicholas R Wilcken
    NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
    Med J Aust 186:368-70. 2007
  10. pmc Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort
    James D Best
    Department of Medicine, University of Melbourne Medical School, St Vincent s Hospital, Melbourne, Victoria, Australia
    Diabetes Care 35:1165-70. 2012

Collaborators

Detail Information

Publications30

  1. ncbi request reprint Interpreting the results of a clinical trial
    Anthony C Keech
    NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW
    Med J Aust 186:318-9. 2007
  2. ncbi request reprint Balancing the outcomes: reporting adverse events
    Anthony C Keech
    NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia
    Med J Aust 181:215-8. 2004
  3. ncbi request reprint Urinary albumin levels in the normal range determine arterial wall thickness in adults with Type 2 diabetes: a FIELD substudy
    A C Keech
    NHMRC Clinical Trials Centre, University of Sydney, Sydney NSW 2006, Australia
    Diabet Med 22:1558-65. 2005
    ..The objective of this study was to identify the determinants of carotid intima media thickness (IMT) in patients with Type 2 diabetes...
  4. ncbi request reprint Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial
    A C Keech
    NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia
    Lancet 370:1687-97. 2007
    ..Our aim was to assess whether long-term lipid-lowering therapy with fenofibrate could reduce the progression of retinopathy and the need for laser treatment in patients with type 2 diabetes mellitus...
  5. doi request reprint Cost-effectiveness considerations of cardiovascular therapeutics
    Anthony Keech
    NHMRC Clinical Trials Centre and Department of Cardiology, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia
    Heart Lung Circ 18:118-22. 2009
    ....
  6. doi request reprint Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    Andrew Tonkin
    Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic, Australia
    Am Heart J 163:508-14. 2012
    ..In the FIELD study, comparison of the effect of fenofibrate on cardiovascular disease (CVD) between those with prior CVD and without was a prespecified subgroup analysis...
  7. pmc Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial
    Russell Scott
    Lipid and Diabetes Research Group, Christchurch Hospital, Christchurch, New Zealand
    Cardiovasc Diabetol 10:102. 2011
    ....
  8. pmc Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
    Kushwin Rajamani
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
    Lancet 373:1780-8. 2009
    ..Our aim was to assess the effect of fenofibrate on amputation events in a large cohort of patients with type 2 diabetes...
  9. ncbi request reprint Putting results of a clinical trial into perspective
    Nicholas R Wilcken
    NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
    Med J Aust 186:368-70. 2007
  10. pmc Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort
    James D Best
    Department of Medicine, University of Melbourne Medical School, St Vincent s Hospital, Melbourne, Victoria, Australia
    Diabetes Care 35:1165-70. 2012
    ..We assessed the adequacy of metformin, sulfonylureas, and insulin to maintain glycemic control and their effects on weight...
  11. doi request reprint Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes
    Philip M Clarke
    School of Public Health, University of Sydney, Sydney, New South Wales
    Med Care 47:61-8. 2009
    ....
  12. ncbi request reprint Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study
    Markus Herrmann
    Department of Clinical Biochemistry, Royal Prince Alfred Hospital, Sydney, Australia
    Clin Chem Lab Med 50:2213-9. 2012
    ..This study investigated the relationship between HCY and the risk of VTE in patients treated with fenofibrate...
  13. doi request reprint Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    David C Burgess
    NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia
    Eur Heart J 31:92-9. 2010
    ....
  14. ncbi request reprint Subgroup analysis: application to individual patient decisions
    R John Simes
    NHMRC Clinical Trials Centre, Locked Bag 77, Camperdown, NSW 2050, Australia
    Med J Aust 180:467-9. 2004
  15. ncbi request reprint Subgroup analysis in clinical trials
    David I Cook
    Department of Physiology F 13, University of Sydney, Sydney, NSW 2006, Australia
    Med J Aust 180:289-91. 2004
  16. pmc Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study
    Ru Dee Ting
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
    Diabetes Care 35:218-25. 2012
    ..We investigated fenofibrate's effects on cardiovascular and end-stage renal disease (ESRD) events, according to eGFR, in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study...
  17. ncbi request reprint Multiple analyses in clinical trials: sound science or data dredging?
    Sarah J Lord
    NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia
    Med J Aust 181:452-4. 2004
  18. doi request reprint Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes
    Kwok Leung Ong
    Lipid Research Group, Heart Research Institute, Sydney, New South Wales 2042, Australia
    J Clin Endocrinol Metab 97:4701-8. 2012
    ....
  19. ncbi request reprint Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis
    David C Burgess
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Level 5, Building F, 88 Mallett Street, Camperdown 2050, Sydney, NSW, Australia
    Eur Heart J 27:2846-57. 2006
    ..Atrial fibrillation (AF) is the most common complication after cardiac surgery. We aimed to evaluate, by meta-analysis, all randomized trials testing interventions for preventing AF...
  20. ncbi request reprint Cost-effectiveness of rehabilitation after an acute coronary event: a randomised controlled trial
    Tom G Briffa
    NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia
    Med J Aust 183:450-5. 2005
    ..To estimate the incremental effects on cost and quality of life of cardiac rehabilitation after an acute coronary syndrome...
  21. ncbi request reprint Statistical methods in clinical trials
    Val J Gebski
    NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450
    Med J Aust 178:182-4. 2003
  22. ncbi request reprint Generalising the results of trials to clinical practice
    J Paul Seale
    Department of Pharmacology, Blackburn Building, University of Sydney, Sydney, NSW 2006, Australia
    Med J Aust 181:558-60. 2004
  23. ncbi request reprint Making sense of trial results: outcomes and estimation
    Rachel L O'Connell
    NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW
    Med J Aust 180:128-30. 2004
  24. ncbi request reprint Inclusion of patients in clinical trial analysis: the intention-to-treat principle
    Stephane R Heritier
    NHMRC Clinical Trial Centre, University of Sydney, Camperdown, NSW
    Med J Aust 179:438-40. 2003
  25. ncbi request reprint Clinical trials research in the new millennium: the International Clinical Trials Symposium, Sydney, 21-23 October 2002
    Rhana Pike
    NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450
    Med J Aust 178:316-7. 2003
  26. ncbi request reprint Recruitment to randomised studies
    Wendy E Hague
    NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia
    Med J Aust 178:579-81. 2003
  27. ncbi request reprint Flow of participants in randomised studies
    Burcu Cakir
    NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW
    Med J Aust 178:347-9. 2003
  28. ncbi request reprint Baseline data in clinical trials
    David C Burgess
    NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW
    Med J Aust 179:105-7. 2003
  29. ncbi request reprint Allocation concealment and blinding: when ignorance is bliss
    Peta M Forder
    NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
    Med J Aust 182:87-9. 2005
  30. ncbi request reprint Specifying interventions in a clinical trial
    Jackie K Brighton
    NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW
    Med J Aust 176:281-2. 2002